According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.

According to the Zhitong Finance App, Shiyao Group (01093.HK) announced that phase I clinical trials of the SYS6057 recombinant respiratory syncytial virus (RSV) vaccine (Chinese hamster ovary (CHO cells)) (this product) developed by the Group have officially started in China.